CN108602892A - 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌 - Google Patents

使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌 Download PDF

Info

Publication number
CN108602892A
CN108602892A CN201780008860.1A CN201780008860A CN108602892A CN 108602892 A CN108602892 A CN 108602892A CN 201780008860 A CN201780008860 A CN 201780008860A CN 108602892 A CN108602892 A CN 108602892A
Authority
CN
China
Prior art keywords
antibody
antigen
nivolumab
ctla
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780008860.1A
Other languages
English (en)
Chinese (zh)
Inventor
F.纳桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108602892A publication Critical patent/CN108602892A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780008860.1A 2016-01-27 2017-01-27 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌 Pending CN108602892A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287717P 2016-01-27 2016-01-27
US62/287717 2016-01-27
PCT/US2017/015333 WO2017132508A1 (en) 2016-01-27 2017-01-27 Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent

Publications (1)

Publication Number Publication Date
CN108602892A true CN108602892A (zh) 2018-09-28

Family

ID=58163189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780008860.1A Pending CN108602892A (zh) 2016-01-27 2017-01-27 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌

Country Status (6)

Country Link
US (3) US20210206854A1 (https=)
EP (1) EP3408296A1 (https=)
JP (3) JP2019503387A (https=)
KR (1) KR20180101584A (https=)
CN (1) CN108602892A (https=)
WO (1) WO2017132508A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113945723A (zh) * 2021-10-28 2022-01-18 复旦大学附属中山医院 预测免疫检查点抑制剂治疗相关肺炎发生风险的试剂盒、系统、储存介质及其应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
HRP20250902T1 (hr) 2015-11-18 2025-09-26 Bristol-Myers Squibb Company Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
US20200405806A1 (en) * 2018-02-08 2020-12-31 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
KR102673786B1 (ko) 2018-08-28 2024-06-07 주식회사 엘지에너지솔루션 원통형 전지 및 이의 제조 방법
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
CN117899200B (zh) * 2022-10-18 2025-11-07 华中科技大学 用于增强免疫治疗疗效的药物及其治疗肿瘤之应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
PL2904011T3 (pl) * 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
SG10201900002QA (en) * 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
JP7348708B2 (ja) * 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CA2955612C (en) * 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
TN2019000101A1 (en) * 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
WO2019140150A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV: "History of Changes for Study NCT01454102", 《STUDY NCT01454102(VERSION 35)》 *
SCOTT JOSEPH ANTONIA，ET AL: "Nivolumab(anti-PD-1；BMS-936558，ONO-4538)and ipilimumab in first-line NSCLC：Interim phase I results", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113945723A (zh) * 2021-10-28 2022-01-18 复旦大学附属中山医院 预测免疫检查点抑制剂治疗相关肺炎发生风险的试剂盒、系统、储存介质及其应用
CN113945723B (zh) * 2021-10-28 2024-03-12 复旦大学附属中山医院 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用

Also Published As

Publication number Publication date
JP2019503387A (ja) 2019-02-07
EP3408296A1 (en) 2018-12-05
WO2017132508A1 (en) 2017-08-03
US20260092114A1 (en) 2026-04-02
KR20180101584A (ko) 2018-09-12
US20210206854A1 (en) 2021-07-08
JP2022046649A (ja) 2022-03-23
US20230083487A1 (en) 2023-03-16
JP2024133611A (ja) 2024-10-02

Similar Documents

Publication Publication Date Title
US20260092114A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20250154274A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
US20250011466A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20240238416A1 (en) Use of immune checkpoint inhibitors in central nervous systems neoplasms
US12590153B2 (en) Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
US20220281974A1 (en) Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
TWI912619B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
KR20190015407A (ko) 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
WO2022047412A1 (en) Cell localization signature and immunotherapy
US20260109766A1 (en) Lag-3 antagonist therapy for melanoma
EP4580756A1 (en) Methods of treating non-small cell lung cancer using mesenchymal epithelial transition factor (met)-targeted agents
TW202604568A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination